Endometrial carcinoma represents the most common gynecological cancer in Europe and the USA. Histopathological classification based on tumor morphology and tumor grade has played a crucial role in the management of endometrial carcinoma, allowing a prognostic stratification into distinct risk categories, and guiding surgical and adjuvant therapy. In 2013, The Cancer Genome Atlas (TCGA) Research Network reported a large scale molecular analysis of 373 endometrial carcinomas which demonstrated four categories with distinct clinical, pathologic, and molecular fea-tures: POLE/ultramutated (7% of cases) microsatellite instability (MSI)/hypermutated (28%), copy-number low/endometrioid (39%), and copy‐number high/serous‐like (26%). In the present article, we report a detailed histological and molecular review of all endometrial carcinoma histotypes in light of the current ESGO/ESTRO/ESP guidelines. In particular, we focus on the distribution and prognostic value of the TCGA groups in each histotype.

New pathological and clinical insights in endometrial cancer in view of the updated ESGO/ESTRO/ESP guidelines

Travaglino A
;
2021-01-01

Abstract

Endometrial carcinoma represents the most common gynecological cancer in Europe and the USA. Histopathological classification based on tumor morphology and tumor grade has played a crucial role in the management of endometrial carcinoma, allowing a prognostic stratification into distinct risk categories, and guiding surgical and adjuvant therapy. In 2013, The Cancer Genome Atlas (TCGA) Research Network reported a large scale molecular analysis of 373 endometrial carcinomas which demonstrated four categories with distinct clinical, pathologic, and molecular fea-tures: POLE/ultramutated (7% of cases) microsatellite instability (MSI)/hypermutated (28%), copy-number low/endometrioid (39%), and copy‐number high/serous‐like (26%). In the present article, we report a detailed histological and molecular review of all endometrial carcinoma histotypes in light of the current ESGO/ESTRO/ESP guidelines. In particular, we focus on the distribution and prognostic value of the TCGA groups in each histotype.
2021
2021
Clear cell carcinoma; CTNNB1; Endometrial carcinoma; Prognosis; Serous carcinoma; TCGA; Undifferentiated carcinoma
Santoro, A; Angelico, G; Travaglino, A; Inzani, F; Arciuolo, D; Valente, M; D'Alessandris, N; Scaglione, G; Fiorentino, V; Raffone, A; Zannoni, Gf.
File in questo prodotto:
File Dimensione Formato  
Endometrial-MetaplasticReactive-Changes-Coexistent-with-Endometrial-Hyperplasia-and-Carcinoma-A-Morphological-and-Immunohistochemical-StudyDiagnostics.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 649.04 kB
Formato Adobe PDF
649.04 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11383/2166202
Citazioni
  • ???jsp.display-item.citation.pmc??? 52
  • Scopus 86
  • ???jsp.display-item.citation.isi??? 82
social impact